Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells

Abstract

Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jak1 phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR . 1995 J. Biol. Chem. 270: 27489–27494

  • Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG . 1994 Biochem. Biophys. Res. Commun. 202: 596–605

  • Bromberg J, Darnell JE . 2000 Oncogene 19: 2468–2473

  • Chung J, Uchida E, Grammer TC, Blenis J . 1997 Mol. Cell Biol. 17: 6508–6516

  • Daeipour M, Kumar G, Amaral MC, Nel AE . 1993 J. Immunol. 150: 4743–4753

  • De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . 2000 Br. J. Haematol. 109: 823–828

  • Eilers A, Georgellis D, Klose B, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Decker T . 1995 Mol. Cell. Biol. 15: 3579–3586

  • Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM . 1998 J. Biol. Chem. 273: 18623–18632

  • Gadina M, Hilton D, Johnston J, Morinobu A, Lighvani A, Zhou Y-J, Visconti R, O'Shea JJ . 2001 Curr. Opin. Immunol. 13: 363–373

  • Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR, Ihle JN, Kerr IM . 1995 EMBO J. 14: 1421–1429

  • Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B . 1997 Exp. Hematol. 25: 1367–1377

  • Hanke J, Gardner JP, Dow RL, Changelian PS, Brissete WH, Weringer EJ, Pollok BA, Connelly PA . 1996 J. Biol. Chem. 271: 695–701

  • Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S . 1995 J. Exp. Med. 182: 243–248

  • Hirano T, Ishihara K, Hibi M . 2000 Oncogene 19: 2548–2556

  • Hirano T . 1998 Int. Rev. Immunol. 16: 249–284

  • Ihle JN . 1995 Nature 377: 591–594

  • Karaghiosoff M, Neubauer H, Lassing C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Muller M . 2000 Immunity 13: 549–560

  • Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G . 1994 Nature 368: 339–342

  • Krishnan K, Pine R, Krolewski JJ . 1997 Eur. J. Biochem. 247: 298–305

  • Kumar G, Gupta S, Wang S, Nel AE . 1994 J. Immunol. 153: 4436–4447

  • Leonard WJ, O'Shea JJ . 1998 Annu. Rev. Immunol. 16: 293–322

  • Lutticken C, Wegenka UM, Yuan J, Buschmann Y, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, Horn F . 1994 Science 263: 89–92

  • Matsuda T, Fukada T, Takahashi-Tezuka M, Okuyama Y, Fujitani Y, Hanazono Y, Hirai H, Hirano T . 1995a J. Biol. Chem. 270: 11037–11039

  • Matsuda T, Takahashi-Tezuka M, Fukada T, Okuyama Y, Fujitani Y, Tsukada S, Mano H, Hirai H, Witte ON, Hirano T . 1995b Blood 85: 627–633

  • Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM . 1996 Nature 379: 645–648

  • Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JN, Kishimoto T, Taga T . 1994 Proc. Natl. Acad. Sci. USA 91: 2285–2289

  • Nosaka T, Kitamura T . 2000 Int. J. Hematol. 71: 309–319

  • Ogata A, Chauhan D, Teoh SP, Urashima M, Schlossman RL, Anderson KC . 1997 J. Immunol. 159: 2212–2221

  • Parganas E, Wang D, Stravopodis D, Topham DJ, Marine J-C, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN . 1998 Cell 93: 385–393

  • Pear WS, Nolan GP, Scott ML, Baltimore D . 1993 Proc. Natl. Acad. Sci. USA 90: 8392–8396

  • Rane SG, Reddy EP . 2000 Oncogene 19: 5662–5679

  • Schuringa JJ, Jonk LJ, Dokter WH, Vellenga E, Kruijer W . 2000 Biochem. J. 347: 89–96

  • Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB . 1998 Proc. Natl. Acad. Sci. USA 95: 11107–11112

  • Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn B, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD . 1994 Science 263: 92–95

  • Treon SP, Anderson KC . 1998 Curr. Opin. Hematol. 5: 42–48

  • Ui M, Okada T, Hazeki K, Hazeki O . 1995 Trends Biochem. Sci. 20: 303–307

  • Yang Y, Vanin EF, Whitt MA, Fornerod M, Zwart R, Schneiderman RD, Grosveld G, Nienhuis AW . 1995 Hum. Gene Ther. 6: 1203–1213

  • Zhang XK, Blenis J, Li HC, Schindler C, Chenkiang S . 1995 Science 267: 1990–1994

Download references

Acknowledgements

We thank JJ Krolewski (University of California, Irvine, CA, USA) for Tyk2 cDNA plasmids and L Samelson (NIH, Bethesda, MD, USA) for helpful discussion and comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stuart Rudikoff.

Additional information

This study is a ‘United States Government Work’ paper, as identified by the US Copyright Act

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kopantzev, Y., Heller, M., Swaminathan, N. et al. IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21, 6791–6800 (2002). https://doi.org/10.1038/sj.onc.1205815

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205815

Keywords

This article is cited by

Search

Quick links